Ipsen (XPAR:IPN) Net Interest Margin (Bank Only) %


XPAR:IPN Ipsen SA XPAR:IPN
96 GF Score
Price €162.70
GF Value €134.33
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ipsen Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

XPAR:IPN
96GF Score
Ipsen SA XPAR:IPN
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipsen (XPAR:IPN) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €162.70 is trading 21.1% above its estimated GF Value™ of €134.33. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for XPAR:IPN:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €134.33 vs. price of €162.70 (21.1% above fair value)
  • GF Score™: 96/100 with 7 warning signs

No single metric tells the full story. See the XPAR:IPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
96GF Score

Get the complete analysis for XPAR:IPN

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€162.70
Price
€134.33
GF Value